News

Article

CSSi LifeSciences and BioMARC Partner to Accelerate Biologics Manufacture

Author(s):

The partnership will focus on providing practical information to clients on the development of biologics and vaccines.

The Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC), a nonprofit contract manufacturing service unit owned and operated by Colorado State University, announced it will work with CSSi LifeSciences to map out clinical development solutions and guidelines for cost-effective good manufacturing practices (GMP).

So far, BioMARC has “brought a diagnostic parenteral product through clinical trial and commercial production (including PAI [preapproval inspection]), manufactured a virus vaccine for a Phase I clinical study, established several master and working cell or virus banks, developed and qualified cell-based and analytical assays for product testing and release, and established a controlled process for manufacturing a vaccine product for preclinical studies in non-human primates bridging to a Phase I study in humans,” according to a press release.

CSSi has performed similar lifecycle management tasks for clients, and says it has helped with the development of more than 500 medical products, including biologics.

"Our combined capabilities will provide a fully-integrated, one-stop manufacturing solution for the accelerated preclinical, manufacturing, and clinical testing of biological therapeutics, novel vaccines, and diagnostic products intended for use in humans," said Raymond Goodrich, PhD, executive director, infectious disease research center, BioMARC.
 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content